News & Updates

Short-term treatment with zolpidem or zopiclone in older patients with Alzheimer’s disease and insomnia appears beneficial, even though safety and tolerance issues have yet to be personalized in healthcare settings and further investigated in subsequent trials, according to a study.

Mild-to-moderate COVID-19 during pregnancy does not appear to affect the foetal brain, according to a prospective study presented at RSNA 2021.

Patients on older antiplatelet or anticoagulant agents who sustain head trauma may be at an increased risk of delayed post-traumatic intracranial haemorrhage (ICH) than those on direct oral anticoagulants (DOACs), according to a retrospective study presented at RSNA 2021.

In individuals who had been on antidepressant therapy for at least 9 months but felt well enough to consider discontinuing, the risk of relapse of depression was greater among those who stopped vs those who carried on with their current regimen, the ANTLER* trial has shown.

In individuals with clinically diagnosed mild-to-moderate Alzheimer’s disease (AD), treatment with the angiotensin II receptor blocker (ARB) losartan for 12 months did not reduce the rate of brain atrophy, findings from the phase II RADAR* trial suggest.

A daily 100 mg dose of aspirin for 7 years did not reduce the risk of dementia in individuals with diabetes and no history of cardiovascular disease (CVD), according to results of the ASCEND* study presented at AHA 2021.

Parkinson’s disease (PD) significantly impairs activity even when patients are in their natural environment, according to a recent real-world study.